Aquestive Therapeutics, Inc. AQST Other — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s other — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s other — R&D?
- Aquestive Therapeutics, Inc. (AQST) reported other — R&D of $319K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s other — R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s other — R&D decreased by 41.6% year-over-year, from $546K to $319K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s other — R&D?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s other — R&D has grown at a 7.4% compound annual growth rate (CAGR), from $1.93M to $2.23M.
- What does other — R&D mean?
- This metric represents the costs incurred by the segment for scientific research and experimental development activities aimed at discovering or improving products. It captures the investment in innovation and pipeline advancement specifically allocated to this business unit. Monitoring this spend helps investors assess the segment's commitment to long-term product viability and technological differentiation.